Posted on

Juventas Therapeutics is developing novel regenerative medicine technologies for treatment of cardiovascular disease, discovered by Cleveland Clinic Cardiologist Marc Penn, M.D., Ph.D. The company’s lead product, Stromal Derived Factor-1 significantly increases cardiac function through promoting cell survival and revascularization post myocardial infarction.